• About
    ▼
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    ▼
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Publications
  • Pipeline
    ▼
    • Overview
    • Ulviprubart
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact
About

About

Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

  • About
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Publications
  • Pipeline
    • Overview
    • Ulviprubart
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact

Tubridy, Karen

December 13, 2022

Karen Tubridy is the Chief Operating Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics. Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She has had responsibility for driving global program strategies to IND, NDA and J-NDA filings. In addition, she has had responsibility for oversight of drug development operations including the build out of core R&D infrastructure and quality systems. Previously, she held senior positions in clinical and regulatory operations at Inspiration Biopharmaceuticals, Taligen Therapeutics (acquired by Alexion) and Syntonix Pharmaceuticals (acquired by Biogen). She held a senior position at AVANT Immunotherapeutics directing several vaccine programs and held positions of increasing responsibility in clinical research and medical affairs at Genetics Institute/Wyeth Pharmaceuticals, where she directed hematology and oncology programs. Karen holds a BS in pharmacy and a PharmD from the Massachusetts College of Pharmacy and Allied Health Sciences.

Karen Tubridy, PharmD

Chief Operating Officer

x

Karen Tubridy, PharmD

Chief Operating Officer

Karen Tubridy is the Chief Operating Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics. Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She has had responsibility for driving global program strategies to IND, NDA and J-NDA filings. In addition, she has had responsibility for oversight of drug development operations including the build out of core R&D infrastructure and quality systems. Previously, she held senior positions in clinical and regulatory operations at Inspiration Biopharmaceuticals, Taligen Therapeutics (acquired by Alexion) and Syntonix Pharmaceuticals (acquired by Biogen). She held a senior position at AVANT Immunotherapeutics directing several vaccine programs and held positions of increasing responsibility in clinical research and medical affairs at Genetics Institute/Wyeth Pharmaceuticals, where she directed hematology and oncology programs. Karen holds a BS in pharmacy and a PharmD from the Massachusetts College of Pharmacy and Allied Health Sciences.

Privacy Site Credits Terms of Use

© 2025 Abcuro